Training Program on Development of Medications for Substance Use Disorder

这个T32应用程序，药物发现中心“药物开发培训计划， 物质使用障碍（SUD）”，是提供广泛的培训，博士生和博士后科学家对药物 发展为SUD。培训计划的基本原理是由社会经济负担和医疗需求驱动的 这与美国和全球缺乏安全有效的药物来治疗SUD有关。培训 该计划融合了导师，课程和研究活动在一个国家的最先进的设施设置。的 培训的目标是使受训者成为富有成效的生物医学研究科学家， SUD药物治疗研究的专业知识。该培训计划的主要地点是药物中心 发现（CDD）在东北大学，具有独特的技术容纳在一个凝聚力的单位，包括， 高通量合成化学和药理活性筛选;基于质谱 基因组学、蛋白质组学和代谢组学，以及生物分析;高分辨率NMR技术; 和体内MRI成像。值得注意的是，CDD培训计划的教师包括哈佛医学的SUD研究人员 学校和姆克林精神病医院，以及塔夫茨大学和医疗中心。此外，CDD 培训计划顾问包括来自制药和生物技术的药物开发科学家 波士顿的工业区。所有参与机构都在8英里半径内， 波士顿大都会区。该培训计划提出了一个首演发现和翻译节点， 解决与明显缺乏有效的类阿片药物有关的惊人的发病率和死亡率问题 使用障碍和完全缺乏与大麻素相关的SUD的批准药物， 精神兴奋剂-似乎旧药物的再利用并没有起作用，缺乏新的药物， 制药行业和联邦实验室为我们的学术培训提供了强有力的理由 SUD新药开发计划，其独特的多学科，多机构 approach.培训计划的一个独特之处是初级教师的参与，包括来自 NIDA校内项目药物开发分支，为下一代SUD提供药物 药物开发科学家培训计划教师协助前和博士后学员发展 科学诚信，协作，演讲技巧，以及方法学方面的专业知识， 包括合成化学，分子和行为药理学，药物药代动力学和代谢， “组学”（药物基因组学、蛋白质组学、代谢组学）和神经成像。除了核心的研究伦理 培训期间，将举行道德操守圆桌讨论会。培训计划的其他特点包括 博士后-博士前实习生合作，实习生研讨会系列，以及实习生参与SUD 科学家们在年度CDD/NIDA主办的研讨会上，药物滥用的化学和药理学。

This T32 application, the Center for Drug Discovery “Training Program on Medications Development for Substance Use Disorder (SUD)”, is to provide broad training to PhD students and postdoctoral scientists on drug development for SUD. The Training Program rationale is driven by the socioeconomic burden and medical need associated with the lack of safe and effective medicines to treat SUD in the US and globally. The Training Program blends mentorship, coursework, and research activities in a setting with state-of-the-art facilities. The goal of training is to equip trainees to develop as productive biomedical research scientists, with consummate expertise in SUD pharmacotherapies research. The main locus of this training program is the Center for Drug Discovery (CDD) at Northeastern University that has unique technologies housed in one cohesive unit, including, high-throughput synthetic chemistry and pharmacological activity screening; mass spectrometry-based genomics, proteomics and metabolomics, as well as, bioanalytical analysis; high-resolution NMR technologies; and in vivo MRI imaging. Notably, CDD Training Program faculty includes SUD researchers at Harvard Medical School and McLean Psychiatric Hospital, as well as, at Tufts University and Medical Center. Moreover, CDD Training Program consultants include drug development scientists from the pharmaceutical and biotechnology industrial community in Boston. All participating institutions are within an 8-mile radius of each other in the metropolitan Boston area. The Training Program presents a premiere discovery and translational node to address the appalling morbidity and mortality associated with apparent lack of effective medications for opioid use disorder and complete absence of approved medications for SUD associated with cannabinoids and psychostimulants—it appears that repurposing of old drugs has not worked and the lack of novel medicines from pharmaceutical industry and federal laboratories provides strong rationale for our academic-based training program on novel medication development for SUD, with its unique multi-disciplinary, multi-institutional approach. A unique feature of the Training Program is engagement of junior faculty, including, from the Medications Development Branch of the NIDA Intramural Program, to provide for the next generation of SUD medication development scientists. Training Program faculty assist pre- and postdoctoral trainees to develop scientific integrity, collaboration, grantsmanship, and presentation skills, as well as, expertise in methodologies, including, synthetic chemistry, molecular and behavioral pharmacology, drug pharmacokinetics and metabolism, “omics” (pharmacogenomics, proteomics, metabolomics), and neuroimaging. In addition to core research ethics training, there will be ethics roundtable discussions. Some other features of the Training Program include postdoctoral–predoctoral trainee collaboration, a trainees’ seminar series, and trainee engagement with SUD scientists at the annual CDD/NIDA-sponsored symposium, Chemistry and Pharmacology of Drug Abuse.